Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of tislelizumab in
combination with sitravatinib compared with docetaxel in participants with locally advanced
or metastatic non-small cell lung cancer (NSCLC) who have disease progression following
platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell
death ligand-1 (PD-L1) antibody, with the anti-PD-(L)1 antibody administered in combination
with or following platinum-based chemotherapy.